Company intelligence / Profile preview
Therion Biologics
Cambridge, Massachusetts, United Statestherion.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Therion Biologics developed poxvirus-based therapeutic vaccines targeting various cancers. Its lead programs were PANVAC-VF (Phase III, pancreatic cancer) and PROSTVAC-VF (Phase II, prostate cancer). The company also had clinical-stage programs in colorectal, ovarian, breast, and lung cancers. Clinical data from pivotal trials were expected in the mid-to-late 2000s but the company ceased operations before commercialization.
- Therapeutic areas
- Oncology
- Modalities
- Recombinant vector vaccineTherapeutic vaccineVaccine
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Aventis Pasteur [now Sanofi Pasteur]National Cancer Institute [NCI]Network of clinical institutions [academic/hospital partners not individually listed]
Beyond the preview
Go deeper on Therion Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Therion Biologics.